Company Name: Aptamer Group Plc (LSE:APTA)

Key Highlights

  • Aptamer Group Plc (LSE:APTA) shares rose 4.84% on 2 October 2026.
  • The York-based company develops Optimer binders, synthetic alternatives to antibodies used in diagnostics, research and therapeutics.
  • Licensing agreements with Twist Bioscience and Alphazyme, plus new diagnostic and radiopharmaceutical programmes, support its commercial story.
  • Full-year results for the year ended 30 June 2026 are expected in the coming weeks, keeping the stock on watch lists.

Why Aptamer Group Is in Focus Today

Aptamer Group Plc (LSE:APTA), the developer of next-generation synthetic binders for the life sciences industry, ended 2 October 2026 up 4.84%. The move kept the micro-cap biotech in view among investors tracking UK-listed life sciences stocks, where small share price moves can reflect shifting expectations around licensing revenue.

No new company announcement was identified for the session. The rise appears linked to positioning ahead of full-year results for the year to 30 June 2026, which are expected around the third week of October.

Key Reasons Behind the Share Price Move

Investors continue to focus on Aptamer's shift from a pure fee-for-service model towards a Business that also earns licensing income. The company has signed licensing agreements with Twist Bioscience and Alphazyme and previously reported its first cash licensing receipts. It has also highlighted Optimer technology being used within a launched library preparation kit, an example of its binders reaching commercial products.

Pipeline news has added to interest. In July 2026, Aptamer initiated an Ebola diagnostic test programme. In June 2026, it announced a research collaboration with Imperial College London, and it earlier launched a targeted radiopharmaceutical programme, an area attracting growing attention across global healthcare markets.

The company works with all of the top 10 global pharmaceutical companies and operates in the large and growing market for antibody alternatives. Optimer binders are designed to offer high affinity, specificity and stability, which can make them attractive for diagnostics and targeted therapies.

Funding and Financial Position

In March 2026, Aptamer raised around £4.3 million before expenses through a placing, subscription and retail offer at 0.6p per share, giving it Working Capital to pursue its strategy of growing fee-for-service Revenue and licensing higher-value assets.

Revenue remains modest. The company reported revenue of £1.20 million for FY25, up 40% year on year, and first-half FY26 revenue of £828,000, up 27%. Losses continue, with a net loss of £1.15 million in the first half. The Market Capitalisation was around £20 million in August 2026.

What Investors Are Watching

The upcoming full-year results are the main near-term catalyst. Investors will look for revenue growth, the scale of licensing income, cash runway and progress in converting partnerships into recurring royalties. Updates on the Ebola diagnostic programme, the radiopharmaceutical work and any new pharmaceutical collaborations will also be closely followed.

Risks are significant. Aptamer remains loss-making, depends on external funding and has a history of dilution through share issues. Licensing timelines can be long and uncertain, and the shares have been volatile.

Outlook

Aptamer Group Plc (LSE:APTA) gained 4.84% on 2 October 2026 as investors positioned ahead of full-year results, with licensing agreements and new diagnostic programmes supporting interest. The pace at which partnerships translate into sustainable revenue will determine whether recent momentum can be maintained.